Genentech, Inc., Herceptin (Trastuzumab)
This MDL consolidates claims brought by cancer-treatment providers alleging that the manufacturer of the oncology drug Herceptin mislabeled multi-dose vials, representing a specific concentration and volume of active drug that the vials did not actually contain, resulting in providers receiving less usable medication per vial than the labeling promised. Centralized in the Northern District of Oklahoma in 2016, the docket carries 12 pending actions and has already produced a significant appellate ruling: in May 2020, the Tenth Circuit reversed a grant of summary judgment for the manufacturer, which had argued the claims were preempted by federal drug-labeling law, and remanded the matter for further proceedings.
What drives resolution risk in this docket now is meaningfully narrower than when it began: the central legal defense that threatened to end the litigation outright, federal preemption, was rejected on appeal, leaving state-law overfill and mislabeling claims to proceed on their merits. That shifts the remaining analysis toward factual and damages questions, how much of a shortfall actually existed and what it cost each provider, rather than a threshold legal question capable of resolving the entire docket at once.
For anyone tracking how a single appellate ruling can reshape an MDL's resolution trajectory, this docket is a clear example: a preemption defense that succeeded at the district court level was reversed on appeal, converting what had been an existential threat to the litigation into a more conventional merits-and-damages dispute. Criterica Intelligence's platform tracks this kind of appellate-ruling-driven shift in resolution posture across every active MDL, since a single circuit decision can change a docket's risk profile more than years of ordinary discovery.
That the manufacturer's multi-dose vial labeling overstated the concentration and volume of active drug the vials actually contained, so cancer-treatment providers received less usable medication per vial than represented.
In May 2020, it reversed a district court's grant of summary judgment for the manufacturer, rejecting the argument that the claims were preempted by federal drug-labeling law, and remanded the case for further proceedings.
It narrows the remaining dispute to factual and damages questions, the extent of any labeling-versus-actual-content shortfall and its cost to each provider, rather than a threshold legal question capable of ending the case outright.
That a single circuit-court decision reversing a dispositive defense can convert an existential threat to a docket into a more conventional merits dispute, a shift in resolution posture Criterica Intelligence tracks across every active MDL.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.